Foghorn Therapeutics Inc. (FHTX) stock
FHTXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 9, 2026Score 11/301% below fair value
$2.07+0.02 (+0.98%)
Close on Nov 13, 2026Market cap $122.93MP/E 29.6Yield –
Foghorn Therapeutics price to sales ratio
The price-to-sales ratio is market cap divided by revenue over the trailing twelve months.
Foghorn Therapeutics's price to sales ratio was 3.3× on Nov 11, 2026, against 11.0× a year earlier. Over the last 5 years it ranged from 3.3× to 480.9×, with a median of 11.7×.
Price to Sales Ratio at the end of each year
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| 2026 | Nov 11, 2026 | 3.3× | −9.1 |
| 2025 | Dec 31, 2025 | 12.5× | +2.2 |
| 2024 | Dec 31, 2024 | 10.3× | +1.9 |
| 2023 | Dec 29, 2023 | 8.4× | −8.6 |
| 2022 | Dec 30, 2022 | 16.9× | −453.2 |
| 2021 | Oct 29, 2021 | 470.1× | – |
See a number that looks wrong?